$171 Million is the total value of Sio Capital Management, LLC's 43 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACAD | New | ACADIA PHARMACEUTICALS INCput | $16,243,000 | – | 563,200 | +100.0% | 9.48% | – |
| SNY | New | SANOFI SAput | $8,492,000 | – | 210,000 | +100.0% | 4.96% | – |
| GSK | New | GLAXOSMITHKLINE PLCsponsored adr | $6,963,000 | – | 180,811 | +100.0% | 4.06% | – |
| GSK | New | GLAXOSMITHKLINE PLCcall | $6,547,000 | – | 170,000 | +100.0% | 3.82% | – |
| EW | New | EDWARDS LIFESCIENCES CORP | $5,154,000 | – | 55,000 | +100.0% | 3.01% | – |
| CAH | New | CARDINAL HEALTH INCput | $5,038,000 | – | 70,000 | +100.0% | 2.94% | – |
| LLY | New | ELI LILLY AND CO | $4,928,000 | – | 67,000 | +100.0% | 2.88% | – |
| ZBH | New | ZIMMER BIOMET HOLDINGS INC | $4,822,000 | – | 46,723 | +100.0% | 2.81% | – |
| WBA | New | WALGREENS BOOTS ALLIANCE INCput | $4,717,000 | – | 57,000 | +100.0% | 2.75% | – |
| AMGN | New | AMGEN INCput | $4,386,000 | – | 30,000 | +100.0% | 2.56% | – |
| ZTS | New | ZOETIS INCput | $4,282,000 | – | 80,000 | +100.0% | 2.50% | – |
| AGN | New | ALLERGAN PLCput | $4,200,000 | – | 20,000 | +100.0% | 2.45% | – |
| ACRS | New | ACLARIS THERAPEUTICS INC | $3,757,000 | – | 138,441 | +100.0% | 2.19% | – |
| PHG | New | KONINKLIJKE PHILIPS NVcall | $3,057,000 | – | 100,000 | +100.0% | 1.78% | – |
| BSX | New | BOSTON SCIENTIFIC CORPcall | $2,606,000 | – | 120,500 | +100.0% | 1.52% | – |
| HUM | New | HUMANA INCput | $2,550,000 | – | 12,500 | +100.0% | 1.49% | – |
| AET | New | AETNA INC | $2,480,000 | – | 20,000 | +100.0% | 1.45% | – |
| BSX | New | BOSTON SCIENTIFIC CORP | $2,455,000 | – | 113,500 | +100.0% | 1.43% | – |
| AMGN | New | AMGEN INC | $2,402,000 | – | 16,430 | +100.0% | 1.40% | – |
| SYK | New | STRYKER CORPput | $2,396,000 | – | 20,000 | +100.0% | 1.40% | – |
| IMMU | New | IMMUNOMEDICS INC | $1,861,000 | – | 506,978 | +100.0% | 1.09% | – |
| FLML | New | FLAMEL TECHNOLOGIES SAsponsored adr | $950,000 | – | 91,413 | +100.0% | 0.55% | – |
| BPMX | New | BIOPHARMX CORP | $428,000 | – | 1,143,400 | +100.0% | 0.25% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VIKING THERAPEUTICS INC | 24 | Q3 2023 | 3.4% |
| UNITED THERAPEUTICS ORD | 23 | Q3 2023 | 8.3% |
| CARDINAL HEALTH ORD | 20 | Q2 2022 | 7.2% |
| SANOFI SA | 19 | Q3 2022 | 9.8% |
| MEDTRONIC PLC | 18 | Q3 2023 | 5.2% |
| CATALYST BIOSCIENCES INC | 18 | Q3 2021 | 17.8% |
| PFENEX ORD | 18 | Q4 2019 | 5.9% |
| AEGLEA BIOTHERAPEUTICS INC | 18 | Q1 2023 | 1.1% |
| HCA HEALTHCARE INC | 17 | Q2 2022 | 5.5% |
| MCKESSON ORD | 17 | Q1 2022 | 6.0% |
View Sio Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Modular Medical, Inc. | February 13, 2023 | 1,091,479 | 10.0% |
| Cellectar Biosciences, Inc. | February 10, 2022 | ? | ? |
| CURIS INC | February 10, 2022 | 3,866,645 | 4.2% |
| Salarius Pharmaceuticals, Inc. | February 10, 2022 | 1,354,291 | 3.0% |
| Larimar Therapeutics, Inc. | February 16, 2021 | 188,661 | 1.2% |
| ACHIEVE LIFE SCIENCES, INC. | February 14, 2020 | ? | ? |
| Bionano Genomics, Inc | February 14, 2020 | 1,210,821 | 4.6% |
| Brickell Biotech, Inc. | February 14, 2020 | ? | ? |
| Trillium Therapeutics Inc. | February 14, 2020 | 2,751,186 | 9.8% |
| ZAFGEN, INC. | February 14, 2020 | 2,283,164 | 6.1% |
View Sio Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| SC 13G | 2023-02-13 |
View Sio Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.